1. Introduction
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality in Europe [
1]. Acute coronary syndrome (ACS) represents a life-threatening manifestation of CVDs [
1]. Patients with ACS are treated with an interventional approach by performing immediate coronary angiography and percutaneous transluminal coronary angioplasty (PTCA) with stent implantation [
2,
3].
Based on the guidelines of the European Society of Cardiology (ESC), dual antiplatelet therapy (DAPT) for up to 12 months is recommended for patients with ACS who underwent PTCA with stent implantation [
2,
3]. The most recent ESC guidelines recommend ticagrelor in a combination with aspirin as a first-line therapy for patients with ACS irrespective of the initial treatment strategy [
2,
3]. The findings of the most recent clinical trials are controversial. The study by Adamski et al. showed that patients with ST-segment elevation myocardial infarction (STEMI) at 1–2 h after receiving a loading dose of ticagrelor were at a greater risk of high platelet reactivity, which is considered an independent risk factor for stent thrombosis [
4]. Other researchers state that ticagrelor is safe to use even if there is a need for treatment with anticoagulants: a combination of ticagrelor, aspirin, and dabigatran can be administered for patients with ACS and non-valvular atrial fibrillation (AF) who underwent PTCA with stent implantation [
5]. However, the administration of dual or triple antiplatelet therapy leads to numerous clinical challenges [
6]. The most frequent clinical challenge associated with ticagrelor administration is its premature discontinuation attributed to sudden-onset dyspnea or bleeding [
7]. It is well-known that ticagrelor causes dyspnea and can be responsible for bleeding; only the incidence of these adverse events differs. Discontinuation of ticagrelor attributed to these causes leads to an increased risk of stent thrombosis and recurrent ACS [
6,
7]. Stent thrombosis and recurrent ACS are associated with significantly greater mortality, longer hospital stay, and worse functional status and quality of life in patients [
7].
Ticagrelor is a cyclopentyltriazolo-pyrimidine (CPTP) that directly and reversibly binds to P2Y
12 receptors. The drug reversibly inhibits the binding of endogenous adenosine diphosphate (ADP) to platelet membrane-bound P2Y
12 receptors and blocks platelet aggregation. The maximum plasma concentration of ticagrelor is reached within 1.3–2 h, and the mean elimination half-life is 7–12 h. Ticagrelor is metabolized to its active metabolite, AR-C124910XX. Ticagrelor and its active metabolite are highly bound to plasma proteins (99.8%); the bioavailability of ticagrelor is about 36%. Ticagrelor-related dyspnea of varying severity usually appears suddenly 2–3 h after drug administration and lasts for several hours, days, or the whole period of drug use. It is directly associated with the maximum plasma concentration of the drug [
8,
9,
10].
Drugs of the thienopyridine class (clopidogrel, prasugrel) bind to P2Y
12 receptors irreversibly and, therefore, inhibit platelet aggregation longer than ticagrelor (for the entire lifespan of platelets, i.e., 7–10 days) [
11]. Clopidogrel is metabolically activated in the liver, and its antiplatelet effect directly depends on a genetic polymorphism. Prasugrel exhibits a more consistent and less metabolism-dependent antiplatelet effect but is associated with a significantly higher risk of bleeding [
11]. The results of large-scale PLATO, DISPERSE-2, RESPOND, and ONSET/OFFSET clinical trials showed that ticagrelor in combination with aspirin was superior to a combination of clopidogrel and aspirin in reducing the incidence of cardiovascular death, recurrent myocardial infarction, and stroke [
12,
13,
14,
15]. The most recent data indicate that enzymes encoded by
CYP2C19 and
SLCO1B1 can have an impact on the rate of elimination of M8, a ticagrelor metabolite, and the clinical effect of ticagrelor itself [
16]. However, in the PLATO trial,
CYP2C19 and
ABCB1 variants were not significantly related to the antiplatelet effect of ticagrelor [
17].
An analysis of the literature related to ticagrelor has revealed that different enzymes may be involved in determining the therapeutic effect of ticagrelor. Nie et al. showed that
CYP4F2 rs2074900 had an effect on the pharmacokinetics of ticagrelor [
18]. Our previous studies showed [
16,
19] that
CYP4F2 variants may determine bleeding during ticagrelor therapy. CYP4F2 may participate in the resolution of inflammation after myocardial infarction [
20]. The pleiotropic effects of ticagrelor could also be related to beneficial cyclooxygenase-2 (COX2) activation. In contrast, aspirin may reduce the activity of COX2 [
21].
Plasminogen activator inhibitor-1 (PAI-1) slows down the activity of the fibrinolysis system and contributes to thrombus formation. The study by Reiner et al. showed that ticagrelor may reduce the activity of PAI-1 [
22]. Ticagrelor blocks platelet P2Y
12 receptors, inhibits platelet activation, and, finally, aggregation through binding α2β3 receptors, which bind fibrinogen [
23]. In addition, the study by Gasecka et al. showed that ticagrelor may reduce the release of extracellular vesicles (EVs) [
24]. During acute myocardial infarction, platelets, endothelial cells, and leukocytes release EVs that contain pro-thrombotic enzymes such as fibrinogen. Studies showed that about twice higher EV concentrations were present in patients with acute myocardial infarction as compared to healthy ones [
25].
Different studies suggest that 1 in every 20 patients treated with ticagrelor experiences dyspnea of varying intensity [
7,
26,
27]. The causes of ticagrelor-related dyspnea remain unknown. Dyspnea can be mild, moderate, and severe, manifesting in 56.5, 28.3, and 15.2% of patients, respectively [
28]. Ticagrelor-related dyspnea can last less than 24 h or can persist over the course of the treatment. Up to 6% of patients with moderate or severe dyspnea discontinue ticagrelor prematurely more frequently or ticagrelor is changed to a less effective combination of clopidogrel and aspirin [
6,
7].
In clinical practice, dyspnea caused by pulmonary, cardiac, and metabolic diseases is most common [
29]. There are several clinical trials during which cardiac and pulmonary function was investigated in patients with ACS or stable angina pectoris, receiving ticagrelor or clopidogrel. The findings of these clinical trials have shown that dyspnea is not related to drug-induced impairment of pulmonary and cardiac function or acidosis [
10,
30]. The incidence of ticagrelor-related dyspnea was the same in both patients with chronic heart failure or chronic obstructive pulmonary disease and those without these diseases [
31]. Up to date, the two most plausible hypotheses explaining the potential mechanisms of ticagrelor-induced dyspnea have been debated [
10,
32]. In the literature, the greatest attention is paid to a structural similarity between ticagrelor and adenosine, activation of adenosine receptors (A1R), and stimulation of vagal C fibers via receptors. Other authors state that ticagrelor can induce dyspnea via P2Y
12 receptors present on vagal C fibers themselves. Some literature sources mention the third cause of dyspnea, i.e., ticagrelor-induced release of adenosine triphosphate (ATP) from erythrocytes; however, this hypothesis is less plausible (
Figure 1) [
10,
32].
The most plausible hypotheses explaining the causes for the occurrence of ticagrelor-related dyspnea are as follows [
10,
32]:
- 1.
An increase in extracellular adenosine levels.
One of the possible causes of dyspnea is related to the effect of adenosine on specific receptors in the respiratory system, resulting in the stimulation of specific sensory receptors. Adenosine receptors are abundantly expressed in all tissues, including the myocardium, nervous system, kidneys, and respiratory system. Purine receptors P1 and P2, so-called adenosine receptors, are specific to adenosine. There are four known types of P1 adenosine receptors: A1, A2A, A2B, and A3. Activated P1 receptors interact with vagal receptors in the lungs and airways, which leads to airway smooth muscle contraction and the sensation of dyspnea. Sensory receptors in the airways are innervated by the vagal nerve and consist of myelinated and unmyelinated C fibers and stretch receptors. Unmyelinated C fibers (type J receptors) provide sensory input from the airways to lung structures. Vagal C fibers in the lungs are involved in the development of tachypnea and dyspnea.
The effect of an activated adenosine receptor depends on receptor and tissue systemic innervation. An increase in adenosine levels activates A1R receptors, which mediate airway smooth muscle contraction. Activation of A1R receptors stimulates sensory receptors in lung tissue, causing the sensation of dyspnea and cough. A2B receptors are linked to inflammation and bronchoconstriction due to mast cell degranulation (release of specific mediators), leading to the development of bronchospasm and dyspnea [
10,
32].
- 2.
Dyspnea is caused via P2Y12 receptors.
P2Y
12 receptors are present not only on the outer membrane of platelets but are also abundant on the cells of other tissues (endothelium, smooth muscles, and neurons) and microglia in the central nervous system. Inhibition of P2Y
12 receptors on neurons and glial cells leads to increased signaling of vagal C fibers and glial cells to the central nervous system. Glial cells can stimulate the central chemoreflex system, eliciting the sensation of acute dyspnea [
10,
32].
- 3.
Dyspnea is associated with ATP release from erythrocytes.
It is thought that ticagrelor induces a directly dose-dependent ATP release from erythrocytes due to changes in pH, which is greater than physiological ATP levels. However, this hypothesis seems to be unlikely as ticagrelor-mediated, erythrocyte-derived ATP is rapidly degraded and has no influence on the occurrence of dyspnea [
10,
32].
Up to date, no clinically relevant biomarkers that would allow prediction of the risk of developing dyspnea or bleeding during treatment with ticagrelor are available [
10]. Moreover, information on pharmacokinetic characteristics in patients with or without dyspnea is scarce [
10]. It is known that aspirin, depending on the consumed amount, exhibits different activities: at low doses, it inhibits platelets; at higher doses, it provides anti-inflammatory effects; and at even higher doses, it causes vasodilation and a toxic effect on the body (respiratory alkalosis, fever, dehydration, acidosis, and shock) [
33]. Most of the sustained episodes of dyspnea resolve with the discontinuation of ticagrelor use and a decrease in ticagrelor plasma levels in all patients [
31]. Based on the accumulated clinical data and experience of our center, ticagrelor-induced dyspnea is a subjective sensation and does not have any negative impact on the patient’s pulmonary function (respiratory rate, spirometry, total lung capacity, oxygen saturation, and other) [
26,
31].
The aim of this study was to determine clinical and genetic factors that would allow prediction of the development of dyspnea in patients receiving ticagrelor. This is important to ensure a safe and continuing use of this drug during the entire treatment period and to prevent the occurrence of complications such as stent thrombosis and recurrent ACS.
4. Discussion
The aim of this study was to determine clinical and genetic factors that would allow prediction of the development of dyspnea in patients receiving ticagrelor.
Based on the results of the large-scale clinical ONSET/OFFSET trial, dyspnea was documented in 38.6, 9.3, and 8.3% of patients receiving ticagrelor, clopidogrel, and prasugrel, respectively [
32,
34]. In our study, dyspnea of varying severity was reported by 34.3% of patients. This study enrolled patients in whom the occurrence of dyspnea due to other causes was unlikely. The severity of dyspnea was evaluated with the modified Borg acute dyspnea scale, which was used in early clinical trials investigating the effect of ticagrelor [
29,
35]. As patients with diabetes mellitus often have other comorbidities that were included in the exclusion criteria, patients with diabetes mellitus in our study accounted for only 12.3%. In agreement with other studies, dyspnea experienced by our patients was not associated with the indicators of heart failure or pulmonary function impairment (confirmed by spirometry, auscultation, or chest X-ray) [
31]. There is evidence that severe renal or hepatic impairment enhances the effect of ticagrelor [
10]. This is in line with the results of our study. Our patients with poorer renal function experienced dyspnea more frequently. Different studies have reported that the incidence of dyspnea is greater in patients with advanced coronary atherosclerosis, thyroid pathology, and older patients, receiving ticagrelor [
10]. Our data also support these statements as, based on epidemiological data, older patients in the entire population had advanced atherosclerotic lesions (two- and three-vessel CAD) and underlying diseases (i.e., hypothyroidism) more frequently.
The findings of our study confirm the results of other authors that treatment of ACS (with beta blockers and angiotensin-converting enzyme inhibitors) defined by the ESC guidelines has no impact on the incidence of ticagrelor-related dyspnea [
31]. Additional analysis of the PLATO trial aimed to investigate possible interactions between ticagrelor and statins (atorvastatin and simvastatin). In the presence of ticagrelor, the simvastatin concentration increased 3–4 times in some patients while the atorvastatin concentration increased marginally (up to 23%) and was considered as clinically irrelevant [
10,
36]. There is evidence that ticagrelor conjugated to glucuronic acid during metabolism in the body can inhibit cytochrome P450 enzymes. The metabolism of ticagrelor is slowed down and its removal from the body is affected [
37], resulting in increased levels of ticagrelor in blood. Even in 2010, the study on human hepatocytes carried out by Feidt et al. demonstrated that statins induced the activities of enzymes belonging to the cytochrome P450 family in the following order: atorvastatin > simvastatin > lovastatin > rosuvastatin. Statins showed the strongest effect on the activity of
CYP2C8 followed by
CYP3A4,
CYP2C9,
CYP2B6, and
CYP2C19 [
38]. In our study, all the patients received treatment with atorvastatin or rosuvastatin. Any-intensity rosuvastatin therapy had no impact on the occurrence of dyspnea while the administration of any dose of atorvastatin lower than 80 mg (or no atorvastatin) increased the likelihood of developing ticagrelor-related dyspnea by more than 2 times. We make an assumption that atorvastatin can reduce the incidence of ticagrelor-related dyspnea by having an effect on ticagrelor metabolism through the dose-dependent activation of P450 enzymes.
Variability in the therapeutic effect of clopidogrel depending on various gene polymorphisms has been documented [
16]. Up to date, there are no significant results of clinical trials that could prove the impact of
CYP2C19,
ABCB1, or other gene polymorphisms on the pharmacodynamic parameters of ticagrelor [
10]. The results of this study show that the
FBG-C148T gene polymorphism was associated with dyspnea. However, multiple logistic regression analysis did not confirm the impact of this variant on the development of dyspnea in the total sample of patients. The synthesis of fibrinogen is regulated by the β-fibrinogen promoter. The -C148T allele is associated with higher levels of inflammatory markers. It is located close to the interleukin-6-response element controlling fibrinogen gene expression during the acute phase of inflammation. Thus, according to Wypasek et al., the
FBG-C148T gene polymorphism is associated with the inflammatory response to advanced atherosclerotic lesion (two- and three-vessel disease) [
39]. Inflammation is one of the most important components of atherosclerotic artery lesion. The more advanced the atherosclerotic lesion, the greater the inflammatory response observed [
40]. In the presence of multiple atherosclerotic coronary lesions, patients usually experience the symptoms of angina pectoris, directly related to the extent of atherosclerotic disease, with dyspnea being one of the typical clinical symptoms [
41]. In our study, we showed that lower platelet activity might be related to the sensation of dyspnea. Platelet activity may also show the activity of the inflammatory system [
42]. Thus, it is probable that the lower rate of sensation of dyspnea is related to the lower concentration and clinical effect of ticagrelor in patients having
FBG variants.
Many clinical trials have proved the impact of the
CYP2C19 polymorphism on predicting the clinical outcomes of patients with ACS who underwent PTCA and stenting and received treatment with a combination of clopidogrel and aspirin. It is known that ticagrelor does not require the activation of the enzyme coded by the
CYP2C19 gene [
10]. Some studies have searched for possible associations between the effect of ticagrelor and the
CYP2C19 polymorphism, but the data reported are controversial. The study by Xie et al. suggested that the
CYP2C19 polymorphism could be related to an increased risk of bleeding in Asian patients who received treatment with ticagrelor [
43]. Teng reported that
CYP2C19 appeared to have no impact on the pharmacodynamic characteristics of ticagrelor [
10]. The pooled analysis of the RESPOND and ONSET/OFFSET clinical trials also showed that the antiplatelet activity of ticagrelor was not related to the
CYP2C19 genotype [
10,
44]. However, there are contradictory data indicating that the
CYP2C19 genetic polymorphism is responsible for the pharmacokinetics of ticagrelor. The
CYP2C19 *1*1 variant was found to be associated with lower platelet aggregation in ticagrelor users [
19,
45]. The results of our study did not confirm an association between the occurrence of dyspnea and the
CYP2C19 variants.
Previous research has found that the
CYP4F2 gene polymorphism has an impact on the effectiveness of treatment with ticagrelor. The
CYP4F2 (rs3093135) T allele was associated with a greater incidence of bleeding events during therapy with ticagrelor [
19]. The TT genetic variant was more common among those patients who reported bleeding events within a 3-month period after hospitalization [
19]. Nie et al. observed that the
CYP4F2 gene polymorphism had a remarkable effect on the pharmacokinetic parameters of ticagrelor [
18]. The findings of our study did not show any association between the occurrence of dyspnea and
CYP4F2 variants.
Based on the accumulated body of knowledge, we made an assumption that the occurrence of dyspnea might be related to high ticagrelor plasma levels, tightly related to platelet aggregation and atorvastatin use [
26,
27]. Large randomized well-controlled studies are required to identify the impact of clinical and genetic factors involved in dyspnea occurrence. Ortega-Paz et al. reported that the occurrence of dyspnea was associated with a higher plasma concentration of ticagrelor [
27]. In our study, we determined the exact range of platelet aggregation (ADP HS), increasing the likelihood of dyspnea occurrence. An ADP HS value of ≤19.5 U increased the odds of developing dyspnea by more than 4 times. To our knowledge, up to date, there are no such similar studies that would confirm the diagnostic value of platelet aggregation testing in the prediction of dyspnea in patients receiving ticagrelor. This hypothesis is indirectly supported by the results of the PEGASUS-TIMI 54 clinical trial. In this clinical trial, the administration of a lower ticagrelor dose (60 mg twice a day) led to a considerably lower rate of dyspnea, but the effect on P2Y
12 receptors remained sufficient [
46].
Some limitations of our study have to be acknowledged. First, it was a single-center study with a small sample size that was not sufficient for the identification of all possible associations. Second, we could not report the results of the evaluation of ticagrelor metabolite levels in urine and plasma as research is still ongoing.